Grace Therapeutics GRCE Income Statement (2011-2026)

NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST
Reported Financials

Grace Therapeutics Quarterly Income Statement

Periods 62 quarters
Latest Sep 2026

Grace Therapeutics reported net income of -$2.13M for the quarter ended Sep 2026. This income statement covers 62 quarters of results from May 2011 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement May2011 Aug2011 Nov2011 Feb2012 May2012 Aug2012 Nov2012 Feb2013 May2013 Aug2013 Nov2013 Feb2014 May2014 Aug2014 Nov2014 Feb2015 May2015 Aug2015 Nov2015 Feb2016 May2016 Aug2016 Nov2016 Feb2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
0.24M0.18M0.13M0.18M0.20M0.17M0.17M0.14M0.14M
Cost of RevenueCost of Rev
Gross Profit
Operating items
Research & DevelopmentR&D
2.18M2.33M2.59M3.29M2.45M1.64M1.10M0.46M1.44M1.69M2.71M2.98M2.19M1.63M0.96M0.57M0.46M0.42M0.70M0.89M
Share-based Compensation (IS)Stock Comp.
0.24M0.20M0.16M0.13M0.30M0.21M0.11M0.18M0.11M
Selling, General & AdministrativeSG&A
1.81M1.82M1.92M1.68M1.59M2.43M1.87M1.63M1.60M1.58M2.26M1.86M1.51M1.55M2.14M1.96M1.99M2.59M1.69M1.41M
Restructuring CostsRestructuring
1.49M
Other Operating ExpensesOther Opex
0.01M0.00M0.22M0.27M0.35M0.40M0.55M0.38M0.60M0.53M0.38M
Operating ExpensesOpex
3.99M4.15M4.51M4.97M4.04M4.07M4.45M2.09M3.04M3.26M4.96M4.83M3.70M3.18M3.09M2.53M2.45M3.01M2.38M2.29M
Operating IncomeOp. Inc
-4.47M-4.40M-4.73M-5.11M-4.25M-38.07M-4.45M-2.09M-3.04M-3.26M-4.96M-4.83M-3.70M-3.18M-3.09M-2.53M-2.45M-3.01M-15.92M-2.29M
Non-operating items
Non Operating Interest Expenses
Goodwill impairment chargesGoodwill Impair.
-13.53M
Interest & Investment IncomeInt & Inv Inc
0.04M0.03M0.04M0.07M0.11M0.13M0.21M0.32M0.25M0.24M0.17M0.14M0.17M0.21M0.17M0.17M0.14M0.14M0.15M
Other Non Operating IncomeOther Non Op Inc.
-1.00M-0.09M-0.01M-0.02M0.00M0.01M1.81M-0.12M1.01M-1.40M-0.35M1.16M-2.65M0.50M-1.44M0.04M-0.01M-0.01M
Non Operating IncomeNon Op. Inc.
0.70M-0.15M-0.04M0.02M0.08M0.12M0.14M-1.63M0.44M-0.79M1.62M0.55M-1.06M2.80M-0.27M1.59M0.13M0.13M0.13M0.15M
Net income details
EBIT
-4.47M-4.40M-4.73M-5.11M-4.25M-38.07M-4.45M-2.09M-3.04M-3.26M-4.96M-4.83M-3.70M-3.18M-3.09M-2.53M-2.45M-3.01M-15.92M-2.29M
EBT
-3.78M-4.55M-4.77M-5.08M-4.16M-37.96M-4.31M-3.72M-2.60M-4.06M-3.34M-4.28M-4.76M-0.38M-3.36M-0.94M-2.32M-2.88M-15.79M-2.14M
Tax ProvisionsTaxes
-0.65M-0.24M-0.16M-0.27M-8.87M-0.29M-0.45M-0.21M-0.89M-0.72M-0.85M-0.61M-1.02M-1.70M0.01M
Income After Tax
-3.78M-3.90M-4.52M-4.93M-3.89M-29.09M-4.02M-3.27M-2.39M-3.17M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.32M-1.18M-15.79M-2.15M
Income from Continuing OperationsIncome (Continuing)
-3.78M-3.90M-4.52M-4.93M-3.89M-29.09M-4.02M-3.27M-2.39M-3.17M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.32M-1.18M-15.79M-2.15M
Consolidated Net IncomeConsol Net Inc.
-3.78M-3.90M-4.52M-4.93M-3.89M-29.09M-4.02M-3.27M-2.39M-3.17M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.32M-1.18M-15.79M-2.13M
Income towards Parent CompanyParent Net Inc
-3.78M-3.90M-4.52M-4.93M-3.89M-29.09M-4.02M-3.27M-2.39M-3.17M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.32M-1.18M-15.79M-2.13M
Net Income towards Common StockholdersNet Income
-3.78M-3.90M-4.52M-4.93M-3.89M-29.09M-4.02M-3.27M-2.39M-3.17M-2.62M-3.43M-4.16M0.64M-3.36M-0.94M-2.32M-1.18M-15.79M-2.13M
Additional items
EPS (Basic)
-0.51-0.64-0.61-0.66-0.52-3.91-0.54-0.43-0.21-0.33-0.24-0.30-0.360.05-0.21-0.06-0.14-0.07-0.91-0.11
EPS (Diluted)
-0.51-0.64-0.61-0.66-0.52-3.91-0.54-0.43-0.21-0.33-0.24-0.30-0.360.05-0.21-0.06-0.14-0.07-0.91-0.11
Shares Outstanding
7.38M6.14M7.39M7.43M7.44M7.44M7.44M7.55M11.51M9.53M10.93M11.51M11.51M12.09M15.92M15.92M16.93M16.51M17.27M20.12M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
7.38M6.14M7.39M7.43M7.44M7.44M7.44M7.55M11.51M9.53M10.93M11.51M11.51M12.09M15.92M15.92M16.93M16.51M17.27M20.12M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
7.38M6.14M7.42M7.44M7.44M7.44M7.44M7.55M9.40M9.40M10.14M10.14M10.14M13.72M13.83M14.13M15.47M16.02M16.27M20.12M
EBITDA
-4.47M-4.40M-4.56M-5.17M-4.24M-38.07M-4.45M-2.09M-3.04M-3.26M-4.96M-4.83M-3.70M-3.18M-3.09M-2.53M-2.45M-3.01M-15.92M-2.29M
Interest ExpensesInt Expense

Grace Therapeutics Income Statement API

Pull Grace Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=GRCE&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY